ArGEN-X has entered into a long-term strategic alliance with Shire Pharmaceuticals that will employ its entire suite of human antibody discovery technologies to focus on multiple targets aligned with Shire’s therapeutic candidates.   Shire will make a total upfront investment of $20.4 million in arGEN-X, and will fund the collaborative research programs at arGEN-X and pay fees, clinical, regulatory and sales milestones, as well as royalties on product sales. Shire will be responsible for c...